SGLT2 inhibition reduces myocardial oxygen consumption

Area of Science:

• Cardiology
• Metabolic Diseases
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibition is linked to reduced cardiac disease risk, but mechanisms remain unclear.
• Improved myocardial energetics is a proposed explanation for the cardioprotective effects of SGLT2 inhibitors.
• Previous studies lacked the statistical power to confirm these effects.

Purpose of the Study:

• To investigate the impact of SGLT2 inhibition on myocardial oxygen consumption and external efficiency.
• To leverage pooled data from randomized clinical trials for enhanced statistical power.

Main Methods:

• Meta-analysis of data from two randomized clinical trials.
• Measurement of myocardial oxygen consumption and external efficiency using positron emission tomography.
• Analysis included 59 participants.

Main Results:

• SGLT2 inhibition significantly reduced myocardial oxygen consumption ( -1.06 mL/100g/min; p=0.01).
• No significant effect was observed on myocardial external efficiency (p=0.13).

Conclusions:

• SGLT2 inhibition decreases resting myocardial oxygen consumption.
• This reduction in oxygen demand may contribute to the observed cardioprotective benefits of SGLT2 inhibitors.